Cryoablation with targeted therapy and immunotherapy for advanced bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your bile duct cancer cannot be removed with surgery or has spread to other parts of the body.
- You have already tried at least one standard treatment (chemotherapy and immunotherapy) and it stopped working or caused too many side effects.
- You have at least one tumor that can be measured on a scan.
- You are 18 years or older.
- Your overall health is reasonably good (able to do daily activities).
- You have not had cryoablation (tumor freezing) treatment before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with advanced bile duct cancer that cannot be removed by surgery. Combining immunotherapy with chemotherapy may help shrink tumors and slow the cancer's growth.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a procedure called cryoablation, which freezes and destroys cancer cells, combined with a targeted therapy drug (anlotinib) for people with advanced bile duct cancer that has not responded to earlier treatments. The goal is to see if this combination can slow the cancer's growth and improve outcomes.
This trial tests a combination of freezing the tumor (cryoablation), an experimental immunotherapy (SHR-1701), and a targeted therapy pill (famitinib) for people with advanced bile duct cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests whether a combination of cryoablation (freezing tumors) and two drugs (lenvatinib and tislelizumab) works better than a standard chemotherapy regimen (FOLFOX) for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer in the liver) that has not responded to or has stopped responding to one prior therapy.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.